Authored by Karl Simpson
Genocea Biosciences, a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company’s board of directors. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and Catabasis Pharmaceuticals. Mr. Bate previously served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc.
Nordic Nanovector announced the appointment of Mr. Luigi Costa as new CEO of the Company. Mr. Costa has over 20 years of international pharmaceutical and biotech experience. Most recently he held the position of Vice President Europe, Middle East and Africa for Onyx Pharmaceuticals, a global biopharmaceutical company based in South San Francisco, California, prior to its acquisition by Amgen. Prior to joining Onyx Pharmaceuticals, he was in-fact an employee of Amgen and held several roles of increasing responsibility with Amgen including Head of International Oncology Franchise, General Manager of Italy and Vice President and General Manager of France.
Paris-based life sciences VC Sofinnova Partners has appointed Henrijette Richter as partner. Richter joins from Novo Seeds, where she was investment director. She spent seven years at the firm, which she helped establish in 2007 in partnership with Danish biotech behemoth Novo and the Novo Nordisk Foundation. She holds a combined PhD and industrial scientist degree in molecular biology from the University of Copenhagen and was awarded the Anna Fuller Postdoctoral Fellowship in molecular oncology. She completed her postdoctoral fellowship at the MIT Center for Cancer Research. She will be working form the Paris HQ office.
to-BBB, a biopharmaceutical company pioneering treatments for devastating rare brain diseases, today announced the appointment of Dr. Anders Harfstrand as Chief Executive Officer. Until recently, Dr. Harfstrand was President and CEO of ADAMA EUROPE. Before that he was the President and CEO of Humabs Biomed SA. From 2007 to 2010, he was the President and CEO of Nitec Pharma AG (now Horizon Pharma), and previously held several executive positions at Serono SA, Pfizer and Pharmacia. “Anders is a significant addition to the to-BBB team,” says Patrick Krol, Chairman of the Supervisory Board and Managing Partner at Aescap Venture.
Raptor Pharmaceuticals has appointed Francoise de Craecker as SVP and Generla Manager European Operations. Francoise was most recently in the employ of Shire where she was VP and GM Europe, Rare Diseases. Francoise is a veteran of the rare diseases business having been involved with starting TKT in Europe prior to its acquisition by Shire in 2005.
Steven Paul, M.D., has been appointed chief executive of Voyager Therapeutics. Paul succeeds interim CEO Mark Levin, a partner at Third Rock Ventures, who will become chairman of Voyager’s board of directors.
Dr. Colin Broom, previously chief scientific officer at ViroPharma, is succeeding Ralf Schmid as Nabriva’s CEO. Schmid will remain a member of the Vienna-based company’s executive management team, serving as chief operating officer and chief financial officer. The European biotech is Chaired by Denise Pollard-Knight and aims to create a US subsidiary.
Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced the appointment of Victor Sandor, M.D., as Chief Medical Officer. Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation. In this role, he was instrumental in the development, approval and commercialization of the first JAK inhibitor. Prior to Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec.